Reporter : Lu Dong
Publisher : Observer Network, re-produced on Minhangshi
Translation, editing : Gan Yung Chyan
/ KUCINTA SETIA
A few days ago, Observer Network obtained a "China Civil Aviation Information Network Co., Ltd. Document" shows that the company has communicated with Sinopharm Group, the current development of SARS-CoV-2 vaccine has made key progress, safety, effectiveness is good. In view of the conditions of emergency vaccination, the former will organize the personnel with specific needs to carry out emergency vaccination under the principle of voluntary vaccination.
Subsequently, the Observer Network called China Civil Aviation Information Network Co., Ltd. (hereinafter referred to as China Hangxin) headquarters, no one answered the phone. At the same time, the contact phone number provided in the above document is also in an unanswered state. Finally, the observer network contacted the office of the board of directors of China TravelSky. The other party said: Information not related to the company's business will not be responded to.
The document issued on 15 June 2020 pointed out that the people who can be given priority in vaccination include:
First-line support for production and R&D, core position staff; airport terminal staff, inspection staff; recent staff who have gone abroad, abroad, and frequent business trips; management and staff who regularly participate in various meetings; the company's epidemic prevention and control leadership team, Various working groups and related staff; the residential area belongs to those who have been classified as medium and high risk in Beijing in recent days; other volunteers can also register.
China Hangxin said in the document that in response to the recent newly diagnosed cases in Beijing, it poses a serious threat to the safety and health of its employees in Beijing. Vaccination with safe and effective vaccines is an important measure to protect the safety and health of the company’s employees in Beijing.
At the end of the document, it is mentioned that in accordance with the principle of voluntary vaccination, vaccination arrangements are based on the number of applicants and the number of vaccines.
On 28 June, the blind review of Phase I/II clinical trials of the SARS-CoV-2 inactivated vaccine jointly developed by Sinopharm Beijing Institute of Biological Products and the Institute of Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention and the phased blind meeting in Beijing And Henan were held simultaneously.
At the meeting, the results of Phase Ⅰ/Ⅱ clinical blinding of the new crown inactivated vaccine of Sinopharm Group Beijing Institute of Biological Products showed that the safety after vaccination is good, and the vaccinators in the vaccine group after different procedures and different doses of vaccinations produce high titers of antibodies . The positive conversion rate of neutralizing antibody reached 100% after two doses on the 0, 21-day program; the positive conversion rate of neutralizing antibody reached 100% after two doses on the 0, 28-day program.
Information from the SASAC website shows that this is another important data obtained from the clinical research of the Chinese biological new crown inactivated vaccine after the blinding of the Phase I/II clinical trial of the new inactivated vaccine against the virus developed by the Wuhan Institute of Biological Products on 16 June.
On the same day, Sinopharm stated on the official website that the situation of epidemic prevention and control is still complicated and severe, and the prevention and control of the new crown epidemic through vaccines is imminent. On 23 June, the launching ceremony of Sinopharm China Bio-SARS-CoV-2 Inactivated Vaccine International Clinical (Phase III) was held in Beijing, Wuhan, and Abu Dhabi, opening a new chapter in international cooperation of SARS-CoV-2 Vaccine.
At the end of May, the Observer Network reported that Liu Jingzhen, secretary of the party committee and chairman of Sinopharm Group, said that 180 volunteers including the principal person in charge of the party and government of the fourth-level enterprise of Sinopharm Group, including himself, took the lead in vaccinating the SARS-CoV-2 inactivated vaccine. The pre-test of volunteers showed that the antibody of the subjects has completely reached the level of resistance to the new corona virus, and the protection rate is 100%. Recently, hundreds of Sinopec cadres and employees voluntarily vaccinated, and they also showed that the vaccine is safe and effective.
No comments:
Post a Comment